Bowled Over for Açaí: OAKBERRY Launches Newly Expanded Signature Bowl Menu
The açaí brand's iconic layered bowls are getting a major expansion, with six flavors of frozen fun and a new matcha chia pudding topping earning permanent spots on OAKBERRY's menu.
MIAMI, April 14, 2025 /PRNewswire/ -- OAKBERRY, the global quick-service superfood brand with always fresh açaí, today launched its all-new Signature Bowl menu, featuring six lusciously layered açaí bowls that put new spins on a classic treat. Starting today, the Signature Bowl menu will be permanently available at OAKBERRY açaí shops nationwide for fans looking to remix, revamp, and refresh their açaí experience.
The expanded menu features the iconic Original and Crunchy bowls along with four all-new, fully customizable layered açaí bowls, giving fans limitless new ideas to help build their perfect bite. Each bowl features an appetizing combination of delicious fruits, nut butters, and premium toppings, from OAKBERRY's new matcha chia pudding for a sweet kick of caffeine, collagen for glowing hair and skin, and whey protein to fuel your workouts.
Whether fans are looking for a bowlful of flavor, texture, wellness, fun, or all of the above, OAKBERRY's new Signature Bowl menu has something for everyone. The menu includes:
'We know our fans are always looking for quicker, easier ways to build their açaí bowls, and the Signature Bowl menu provides the perfect source of inspiration to stir up something new,' said Bruno Cardinali, Global CMO at OAKBERRY. 'We're excited for our fans to enjoy the new bowls and look forward to seeing the unique creations they come up with as well.'
The Signature Bowl menu is the biggest expansion of OAKBERRY's açaí bowl offerings to date and follows the revamp of its smoothie menu in October 2024. While the Original Bowl and Crunchy Bowl have long been a focal point of OAKBERRY's layered açaí bowl menu, the new Signature Bowls reimagine OAKBERRY's premium açaí and toppings in more ways than ever before.
To get a taste of OAKBERRY's new Signature Bowl menu, check out www.oakberry.com/#stores to find an OAKBERRY location near you. For more updates and upcoming menu innovations, be sure to follow @oakberryusa.
About OAKBERRY
OAKBERRY was founded in Brazil in 2016 by Georgios Frangulis and Renato Haidar following a dream to create a quick-service superfood brand that is delicious, easy and fun to eat, and accessible to everyone. That dream became OAKBERRY's refreshing and indulgent menu of açaí bowls and smoothies served up in visually appealing layers of açaí and customizable, unlimited toppings at shops worldwide. OAKBERRY's açaí is sustainably sourced from Brazil's Amazon Rainforest and is an abundant source of energy, rich in antioxidants and organic with no high fructose corn syrup or artificial colors added.
A fast-growing brand with over 700 locations across 40 countries, OAKBERRY'S fully verticalized business model provides flexibility and operational efficiencies for its growing franchise model. To learn more about OAKBERRY, visit https://www.oakberry.com/en-us and follow along on social media at @oakberryusa; for franchise opportunities visit https://oakberryfranchise.com/.
CONTACT:
Haley Silvers
212-994-7532
[email protected]
View original content to download multimedia: https://www.prnewswire.com/news-releases/bowled-over-for-acai-oakberry-launches-newly-expanded-signature-bowl-menu-302427039.html
SOURCE OAKBERRY
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% DZD8586 exhibited significant antitumor activity in heavily pretreated chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients with an objective response rate (ORR) of 84.2% Both golidocitinib and DZD8586 will be featured in oral presentations at ICML 2025, with DZD8586 also presented in an oral session at ASCO 2025 SHANGHAI, June 12, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present research findings on two of its first-in-class hematologic oncology assets—golidocitinib and DZD8586—at the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). These include long-term follow-up data on golidocitinib as a maintenance therapy in peripheral T-cell lymphoma (PTCL) after first-line systemic therapy and pooled analysis results for DZD8586 in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), both selected for oral presentations at ICML. Golidocitinib Shows Potential to Significantly Improve Patient Outcomes in PTCL PTCL patients who achieved tumor response with first-line standard therapy will relapse. Approximately 40% of patients with complete response and 80% with partial response experienced disease progression within 2 years after initial tumor response, and the prognosis of these relapsed patients was very poor. The 24-month follow-up results from JACKPOT26, a prospective, multicenter Phase 2 clinical study of golidocitinib will be unveiled at EHA and featured as an oral presentation at ICML. The data suggest that golidocitinib showed promising efficacy in maintaining and enhancing tumor response with an acceptable and manageable safety profile in patients with PTCLs post first-line therapies. In Cohort 1 (patients with complete response), the 24-month disease-free survival (DFS) rate reached 74.2%, with consistent efficacy observed across different subtypes. In Cohort 2 (patients with partial response), the complete response rate (CRR) was 50.0%, the median duration of response (DoR) was 23.9 months, and the median progression-free survival (PFS) was 17.4 months, with the longest PFS reaching 35.9 months and the patient was still responding. "Golidocitinib, a next-generation oral and highly selective JAK1 inhibitor, addresses a critical unmet need for effective maintenance therapy following first-line treatment in PTCL," said Professor Jie Jin, lead principal investigator of the JACKPOT26 study at the First Affiliated Hospital of Zhejiang University School of Medicine. "Its unique mechanism of action not only delivers strong anti-tumor activity—allowing 50% of patients with partial remission (PR) to achieve complete remission (CR)—but also modulates the tumor immune microenvironment through its anti-inflammatory and immunomodulatory effects. These unique features help delay relapse and extend survival, positioning golidocitinib as a highly promising option for maintenance therapy in PTCL." In addition, golidocitinib has shown encouraging antitumor activities and favorable safety profiles in combination with CHOP in 1st line PTCL patients, as well as in rare T-cell lymphoma subtypes, including relapsed/refractory T-cell large granular lymphocytic leukemia (r/r T-LGLL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). Further studies are warranted to validate the results. DZD8586 Overcomes Multi-Drug Resistance in CLL and other B-NHL A pooled analysis of two phase I/II studies of DZD8586 in CLL/SLL patients previously treated with covalent/non-covalent Bruton's Tyrosine Kinase (BTK) inhibitors and BTK degraders was presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and will be presented at EHA. Subgroup analyses will be presented as an oral presentation at ICML. In heavily pretreated CLL/SLL, DZD8586 achieved an ORR of 84.2%. Tumor response with a manageable safety profile was observed irrespective of prior covalent/non-covalent BTKi, BTK degrader, or BCL-2 inhibitor treatment, and in patients with classic BTK resistance mutations (C481X) as well as other BTK mutations, including kinase-dead mutations. No drug-related bleeding, atrial fibrillation, or major cardiac events observed. A Phase II study of DZD8586 monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at EHA and ICML. Clinical activities from small molecule targeted drugs such as BTK inhibitors have been less than desired for the treatment of DLBCL. Compensatory or redundant pathway activation could be one of the main escape mechanisms. DZD8586, a novel LYN/BTK dual inhibitor, is designed to overcome these limitations by blocking both BTK and LYN signaling pathways, and thus potentially improve therapeutic outcomes. At recommended phase 2 doses (RP2Ds) of 50 mg and 75 mg QD, DZD8586 monotherapy demonstrated promising anti-tumor activity in r/r DLBCL. The majority of patients showed target lesion shrinkage, with a CRR of 35.5%. Complete responders showed durable responses, with 81.8% of patients remaining in response and the median DoR was not reached. Notably, it showed efficacy in both GCB and non-GCB subtypes, supporting its broad therapeutic potential. Dr. Xiaolin Zhang, CEO of Dizal, remarked, "We are excited that golidocitinib and DZD8586 have demonstrated promising potential in PTCL and B-cell non-Hodgkin lymphoma (B-NHL), two areas with substantial unmet clinical needs. The selection of multiple studies for oral presentations at global leading conferences represents a strong recognition of our capabilities in research and development and further affirms our commitment to bringing transformative therapies to patients worldwide." About golidocitinib (DZD4205)Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4). About DZD8586DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). While Bruton's Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. DZD8586 has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL. About DizalDizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deeply rooted in translational science and molecular design, it has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China. To learn more about Dizal, please visit or follow us on Linkedin or X. Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect. ContactsInvestor Relations: ir@ Development: bd@ Contact: pr@ View original content to download multimedia: SOURCE Dizal Pharmaceutical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
NovoLINC Appoints Tech Industry Veteran Bob Wenner as COO to Scale Product for AI Data Center Cooling
Wenner to lead operations, manufacturing, and strategic execution to accelerate NovoLINC's delivery to cool AI data-centers high-power, high-performance chips PITTSBURGH, June 12, 2025 /PRNewswire/ -- NovoLINC, a pioneering thermal technology startup, announced the appointment of Bob Wenner as its Chief Operating Officer and a member of the board of directors. With over 40 years of experience in the data storage industry, Wenner brings operational expertise and experience in scaling novel manufacturing processes to accelerate the company's growth and meet the increasing demand for NovoLINC's breakthrough thermal interface solution. A critical thermal management challenge is rapidly arising at the heart of the race for next-generation AI data centers. Flagship GPUs now demand up to 1,200W per device, with that power density expected to triple in the next two years. Traditional thermal interface materials (TIMs) have become the weakest link in the system, unable to keep pace with the performance and reliability demands of modern AI systems. NovoLINC's breakthrough nanostructured thermal interface solution is engineered to eliminate this bottleneck, and the company is already working with leading semiconductor companies, hyperscalers, and AI infrastructure providers to dramatically improve thermal performance, increase compute reliability, and reduce data center energy consumption in the AI era. "Bob has extensive leadership experience across operations, engineering, and manufacturing; he has driven innovation and operational excellence at the industry's top companies," said Ning Li, Ph.D, CEO and co-founder of NovoLINC. "We are very fortunate to have Bob come on board at this critical time as we are seeing incredible customer pull for our innovation. With his leadership, we will be able to accelerate the delivery of our products to customers." "This is a transformative technology that doesn't come around often," said Wenner. "I'm incredibly excited to be part of NovoLINC and joining a group of very talented and experienced team members. With customers validating our game-changing thermal performance, I can't wait to help our customers break out from today's thermal limitations and extract more performance for the next-generation high-performance chips." "Bob brings exactly the kind of operational leadership we need at this pivotal moment," said Ilja Aizenberg, Principal at M Ventures and member of NovoLINC's board of directors. "His proven track record of translating breakthrough technologies into high-volume production makes him uniquely qualified to help us deliver our thermal solutions at scale." Previously, Wenner served as Head of Worldwide Equipment Development Engineering at Seagate Technology, overseeing all internally developed equipment across global manufacturing sites and teams across the U.S., Singapore, Thailand, Malaysia, and China. In addition, Wenner led R&D budget planning, product development processes, corporate quality initiatives, and strategic acquisitions in the CTO office. Prior to Seagate, Wenner held various leadership positions at IBM and Western Digital. About NovoLINCNovoLINC is a pioneering startup in advanced thermal interface solutions, headquartered in Pittsburgh, PA. NovoLINC has developed an advanced nanostructured materials system and proprietary manufacturing process to revolutionize thermal management for high-performance computing, data centers, automotive, aerospace and power electronics. With a team of industry experts and partnerships with leading technology companies, NovoLINC aims to enable sustainable scaling of semiconductor and data center industries. Interested partners may contact the company via business@ About M Ventures M Ventures is the strategic, corporate venture capital fund of Merck KGaA, Darmstadt, Germany, investing in Biotechnology and Technology. M Ventures covers the areas of Healthcare drug development, Life Science tools, Electronics and Frontier Technology & Sustainability. M Ventures invests - with dual strategic and financial foci - into visionary companies that find new ways to: treat the most challenging diseases, empower scientists with cutting-edge research and development tools, develop new solutions that change the way in which information is accessed, stored, processed, and displayed and address some of the most complex challenges in sustainability and technology convergence. For more information, visit View original content to download multimedia: SOURCE NovoLINC, Inc.
Yahoo
28 minutes ago
- Yahoo
Truth Scan Launches AI Fraud Detection Platform to Combat Deepfake Threats
Delaware-Based Company Offers Real-Time Protection Against Malicious AI Content Targeting Individuals and Businesses DOVER, Del., June 12, 2025 /PRNewswire/ -- According to the FBI, AI-powered cyberattacks are quickly escalating and resulting in "devastating financial losses." Today, Truth Scan, an AI fraud and deepfake detection software company founded in 2024 by Ben Miller and Christian Perry, just launched its new comprehensive AI content verification platform. The company protects against AI-generated fraud by using multimodal detection technology which examines audio and image and video and text content. The API for business verification of content authenticity and a web-based verification platform and browser extension with real-time protection during video calls and internet browsing form the three key solutions of Truth Scan. Truth Scan co-founder Christian Perry says "The solution is a response to an urgent need to combat the massive flood of harmful AI content." "We're seeing a desperately needed defense against a massive amount of malicious AI content that's coming out, scamming people and causing harm out in the world," The platform combats multiple AI threat types (deep fake media, text, and audio) that affect both consumers and organizations in the present day. The platform aims to protect users from AI-generated fake calls that target enterprise leaders, and even elderly victims, for financial extortion and AI video-based reputation damage and deepfake pornography that creates challenges for victims to prove their innocence. The API allows companies to integrate Truth Scan's detection capabilities, but the company also offers protection through its website and browser extension for individual users. The real-time browser extension alerts users immediately about potential AI-generated fraud content encountered during video calls or when watching online media. Perry says that "AI fraud is increasing rapidly while deepfake attacks against innocent people will continue to grow as negative consequences emerge." The launch takes place during a period when AI-powered scams are reported to be increasing across different sectors. Users can verify content authenticity across multiple media types through Truth Scan's multimodal system which delivers complete protection against evolving AI threats. The Delaware-based company Truth Scan provides its AI-generated fraud and misinformation protection services to both individual consumers and enterprise clients. For more information about Truth Scan and its deepfake detection services, visit About Truth Scan Truth Scan established itself as a deepfake detection software company in 2024 to fight against harmful AI content. Through API integration and web-based verification and real-time browser protection, the company delivers multimodal AI fraud detection technology. Truth Scan operates its headquarters from Delaware within the United States. Media Contact:Devan Leos661-361-6346396603@ View original content to download multimedia: SOURCE Truth Scan
